Search Results
Search for other papers by Philippe L Bedard in
Google Scholar
PubMed
Search for other papers by Sandeep K Singhal in
Google Scholar
PubMed
Search for other papers by Michail Ignatiadis in
Google Scholar
PubMed
Division of Medical Oncology and Hematology, Breast Cancer Translational Research Laboratory JC Heuson, Frontier Science (Scotland) Ltd, School of Medicine, Machine Learning Group, Novartis Institutes for BioMedical Research, Breakthrough Breast Research Group, University of Edinburgh, Department of Biostatistics and Computational Biology, Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Search for other papers by Ian Bradbury in
Google Scholar
PubMed
Division of Medical Oncology and Hematology, Breast Cancer Translational Research Laboratory JC Heuson, Frontier Science (Scotland) Ltd, School of Medicine, Machine Learning Group, Novartis Institutes for BioMedical Research, Breakthrough Breast Research Group, University of Edinburgh, Department of Biostatistics and Computational Biology, Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Division of Medical Oncology and Hematology, Breast Cancer Translational Research Laboratory JC Heuson, Frontier Science (Scotland) Ltd, School of Medicine, Machine Learning Group, Novartis Institutes for BioMedical Research, Breakthrough Breast Research Group, University of Edinburgh, Department of Biostatistics and Computational Biology, Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Search for other papers by Benjamin Haibe-Kains in
Google Scholar
PubMed
Search for other papers by Christine Desmedt in
Google Scholar
PubMed
Search for other papers by Sherene Loi in
Google Scholar
PubMed
Search for other papers by Dean B Evans in
Google Scholar
PubMed
Search for other papers by Stefan Michiels in
Google Scholar
PubMed
Search for other papers by J Michael Dixon in
Google Scholar
PubMed
Search for other papers by William R Miller in
Google Scholar
PubMed
Search for other papers by Martine J Piccart in
Google Scholar
PubMed
Search for other papers by Christos Sotiriou in
Google Scholar
PubMed
2003 Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer . Breast Cancer Research and Treatment 82 113 – 123 . doi:10.1023/B:BREA.0000003968.45511.3f . Baselga J Semiglazov
Search for other papers by Lucas Leite Cunha in
Google Scholar
PubMed
Search for other papers by Marjory Alana Marcello in
Google Scholar
PubMed
Search for other papers by Elaine Cristina Morari in
Google Scholar
PubMed
Search for other papers by Suely Nonogaki in
Google Scholar
PubMed
Search for other papers by Fábio Frangiotti Conte in
Google Scholar
PubMed
Search for other papers by René Gerhard in
Google Scholar
PubMed
Search for other papers by Fernando Augusto Soares in
Google Scholar
PubMed
Laboratory of Cancer Molecular Genetics, Adolfo Lutz Institute, Department of Genetics and Evolution, Department of Radiology, Department of Pathology, Laboratory of Investigative and Molecular Pathology (Ciped), Faculty of Medical Sciences, University of Campinas (Unicamp), PO Box 6111, 126 Tessalia Vieira de Camargo Street, Campinas, São Paulo, Brazil
Search for other papers by José Vassallo in
Google Scholar
PubMed
Search for other papers by Laura Sterian Ward in
Google Scholar
PubMed
infiltrating DTC is closely associated with molecular markers of these tumors ( Cunha et al . 2012 a ). Lymph node metastatic tissues had lower levels of B7H1 than the primary tumor, suggesting an exhaustion of T-cell activation. French et al . (2012
Search for other papers by C Montagut in
Google Scholar
PubMed
Search for other papers by I Tusquets in
Google Scholar
PubMed
Search for other papers by B Ferrer in
Google Scholar
PubMed
Search for other papers by J M Corominas in
Google Scholar
PubMed
Search for other papers by B Bellosillo in
Google Scholar
PubMed
Search for other papers by C Campas in
Google Scholar
PubMed
Search for other papers by M Suarez in
Google Scholar
PubMed
Search for other papers by X Fabregat in
Google Scholar
PubMed
Search for other papers by E Campo in
Google Scholar
PubMed
Search for other papers by P Gascon in
Google Scholar
PubMed
Search for other papers by S Serrano in
Google Scholar
PubMed
Search for other papers by P L Fernandez in
Google Scholar
PubMed
Search for other papers by A Rovira in
Google Scholar
PubMed
Search for other papers by J Albanell in
Google Scholar
PubMed
tumour markers or the inclusion of molecular markers – such as Ki67 or topoisomerase IIα – would lead to a higher predictive value ( Burcombe et al . 2005 ). On the other hand, HER2 overexpression is linked to response to adjuvant anthracycline
Search for other papers by A Garolla in
Google Scholar
PubMed
Search for other papers by A Ferlin in
Google Scholar
PubMed
Search for other papers by C Vinanzi in
Google Scholar
PubMed
Search for other papers by A Roverato in
Google Scholar
PubMed
Search for other papers by G Sotti in
Google Scholar
PubMed
Search for other papers by W Artibani in
Google Scholar
PubMed
Search for other papers by C Foresta in
Google Scholar
PubMed
Polymorphic repeat in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Research 57 1194 –1198. Sultan C , Paris F, Terouanne B, Balaguer P, Georget V, Poujol N, Jeandel C, Lumbroso S & Nicolas JC
Search for other papers by Gail S Prins in
Google Scholar
PubMed
prostate cancer risk? Is there a transgenerational risk for prostate cancer as a function of ED exposures? Can we establish molecular markers for ED exposures as they relate to prostate disease risk? Focused research on these and other specific questions is
Search for other papers by Pedro Weslley Rosario in
Google Scholar
PubMed
Search for other papers by Gabriela Franco Mourão in
Google Scholar
PubMed
.1016/j.surg.2017.04.037 ) 29146229 10.1016/j.surg.2017.04.037 Nikiforov YE 2017 Role of molecular markers in thyroid nodule management: then and now . Endocrine Practice 23 979 – 988 . ( https://doi.org/10.4158/EP171805.RA ) 10.4158/EP171805.RA
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Patrick Maisonneuve in
Google Scholar
PubMed
Search for other papers by Alessio Pellegrinelli in
Google Scholar
PubMed
Search for other papers by Federica Grillo in
Google Scholar
PubMed
Search for other papers by Luca Albarello in
Google Scholar
PubMed
Search for other papers by Paola Spaggiari in
Google Scholar
PubMed
Search for other papers by Alessandro Vanoli in
Google Scholar
PubMed
Search for other papers by Giovanna Tagliabue in
Google Scholar
PubMed
Search for other papers by Eleonora Pisa in
Google Scholar
PubMed
Search for other papers by Luca Messerini in
Google Scholar
PubMed
Clinical Research Lab (CRAB), Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Search for other papers by Giovanni Centonze in
Google Scholar
PubMed
Search for other papers by Frediano Inzani in
Google Scholar
PubMed
Search for other papers by Aldo Scarpa in
Google Scholar
PubMed
Search for other papers by Mauro Papotti in
Google Scholar
PubMed
Search for other papers by Marco Volante in
Google Scholar
PubMed
Search for other papers by Fausto Sessa in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
University of Milan, School of Medicine, Milan, Italy
Search for other papers by Giancarlo Pruneri in
Google Scholar
PubMed
Search for other papers by Guido Rindi in
Google Scholar
PubMed
Search for other papers by Enrico Solcia in
Google Scholar
PubMed
Search for other papers by Stefano La Rosa in
Google Scholar
PubMed
Search for other papers by Carlo Capella in
Google Scholar
PubMed
-life pathology reporting. The significant association of several molecular markers, including Rb, p16, p53 CDX2, CD117, ALDH and MMR, that we found in both NEC and non-NEC components seems to confirm and to extend previous studies ( Furlan et al . 2003 , 2013
Search for other papers by Isabelle Laverdière in
Google Scholar
PubMed
Search for other papers by Christine Flageole in
Google Scholar
PubMed
Search for other papers by Étienne Audet-Walsh in
Google Scholar
PubMed
Search for other papers by Patrick Caron in
Google Scholar
PubMed
Search for other papers by Yves Fradet in
Google Scholar
PubMed
Search for other papers by Louis Lacombe in
Google Scholar
PubMed
Pharmacogenomics Laboratory, CHU de Québec Research Center and Faculty of Medicine, Canada Research Chair in Pharmacogenomics, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4720, 2705 Boulevard Laurier, Québec, Québec, Canada G1V 4G2
Search for other papers by Éric Lévesque in
Google Scholar
PubMed
Pharmacogenomics Laboratory, CHU de Québec Research Center and Faculty of Medicine, Canada Research Chair in Pharmacogenomics, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4720, 2705 Boulevard Laurier, Québec, Québec, Canada G1V 4G2
Search for other papers by Chantal Guillemette in
Google Scholar
PubMed
BY Fradet Y Laverdiere I Rouleau M Huang CY Yu CC 2013 Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression . Clinical Cancer Research 19 699 – 709 . ( doi:10
Search for other papers by Zsófia Tömböl in
Google Scholar
PubMed
Search for other papers by Peter M Szabó in
Google Scholar
PubMed
Search for other papers by Viktor Molnár in
Google Scholar
PubMed
Search for other papers by Zoltán Wiener in
Google Scholar
PubMed
Search for other papers by Gergely Tölgyesi in
Google Scholar
PubMed
Search for other papers by János Horányi in
Google Scholar
PubMed
Search for other papers by Peter Riesz in
Google Scholar
PubMed
Search for other papers by Peter Reismann in
Google Scholar
PubMed
Search for other papers by Attila Patócs in
Google Scholar
PubMed
Search for other papers by István Likó in
Google Scholar
PubMed
Search for other papers by Rolf-Christian Gaillard in
Google Scholar
PubMed
Second Department of Medicine, Department of Genetics, First Department of Surgery, Department of Urology, Molecular Medicine Research Group, Gedeon Richter Ltd, Division of Endocrinology, Research Group of Inflammation Biology and Immunogenomics, Faculty of Medicine, Semmelweis University, Szentkirályi Street 46, H-1088 Budapest, Hungary
Search for other papers by András Falus in
Google Scholar
PubMed
Search for other papers by Károly Rácz in
Google Scholar
PubMed
Search for other papers by Peter Igaz in
Google Scholar
PubMed
. Nature 455 58 – 63 . Soon PS McDonald KL Robinson BG Sidhu SB 2008 Molecular markers and the pathogenesis of adrenocortical cancer . Oncologist 13 548 – 561 . Subramanian A Tamayo P Mootha VK Mukherjee S Ebert BL Gillette
Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
Search for other papers by Mijin Kim in
Google Scholar
PubMed
Search for other papers by Chae Hwa Kwon in
Google Scholar
PubMed
Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
Search for other papers by Bo Hyun Kim in
Google Scholar
PubMed
, definite molecular markers are needed to estimate the aggressive progression and prognosis of low-risk PTMC at the initiation of active surveillance. PTMCs can metastasize to regional LNs even in the early stages of the disease, with an incidence of